MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7673
-0.0129
-1.65%
After Hours: 0.9598 +0.1925 +25.09% 16:39 04/03 EDT
OPEN
0.7745
PREV CLOSE
0.7802
HIGH
0.8000
LOW
0.7600
VOLUME
31.23K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.4900
MARKET CAP
15.68M
P/E (TTM)
-0.9755
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NAVB stock price target is 3.500 with a high estimate of 4.000 and a low estimate of 3.000.

EPS

NAVB News

More
  • Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navideas Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates
  • Business Wire · 4d ago
  • Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 03/24 20:19
  • Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
  • Business Wire · 03/20 12:00
  • Navidea Bio +26% premarket on Lymphoseek patent extension
  • Seeking Alpha - Article · 03/20 11:37

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About NAVB

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
More

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.